All In Biotech

Drug Trial Radar · NCT07542314

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (ENHANCE)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • ELEVIDYSDrug

    Administered via an intravenous infusion.

  • SirolimusDrug

    Administered orally.

  • GlucocorticoidsDrug

    Administered orally.

  • AntibioticsDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Number of Participants with ALITime frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.